EEG Biomarkers for OUD: Diagnostic, Prognostic, and Predictive Applications

StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Sep 15, 2025 to Sep 15, 2026 Show 5 more changesShow less
    • Enrollment closed, study ongoing
    • Study completion pushed from Sep 15, 2025 to Sep 15, 2027
    • Study sites: 1 to 3
    • Eligibility criteria expanded, about 22 words
    • Study description revised
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The US is suffering from a national opioid epidemic characterized by significant costs, overdoses, and deaths. Conventional Opioid Use Disorder (OUD) treatments (i.e., pharmacological and psychosocial interventions) are characterized by limited or diminishing efficacy, ceiling effects, and/or serious side effects. The availability of validated OUD biomarkers would be a key step in the development and approval of better treatments. Ultimately, the scarcity of OUD biomarkers represents a significant unmet need in the fight against opioid addiction as recognized by NIDA and the FDA with their support for development of Medical Device Development Tools (MDDT) and biomarker tests for OUD. Advances in neuroimaging techniques, and in particular recent evidence supports electroencephalography (EEG) as a promising candidate to investigate the correlation between addiction and brain state. To address the clear medical and market need for OUD biomarkers, this is a feasibility study to identify and assess potential EEG biomarkers for OUD diagnoses, disease monitoring, and prediction of OUD treatment response.
Trial Details
NCT Number NCT07085351
Lead Sponsor University of Illinois at Chicago
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions
(from sponsor)		 Opiod Use Disorder
Related terms Opioid-Related Disorders
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov